Tecvayli (teclistamab) delivered BCMA targeting as an off-the-shelf antibody, sidestepping the manufacturing time and specialized centers that CAR-T requires in late-line myeloma.
Teclistamab binds BCMA on myeloma cells and CD3 on T cells, bridging them to trigger tumor cell killing as the first BCMA-directed bispecific antibody approved. Weekly subcutaneous injections follow step-up dosing in adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy.
Tecvayli requires REMS-managed step-up dosing because of cytokine release syndrome and neurotoxicity risk, and it later gained reduced dosing frequency for sustained responders. Immediate availability without manufacturing delay is its core advantage over CAR-T.
